Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for acute treatment of migraine in children and adolescents
2020-003517-35Phase 3Active
- Sponsor
- Pfizer
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Rimegepant with Placebo (2 arms). Primary endpoint: Pain freedom at 2 hours in adolescents. Started Feb 2021; status: active.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2020-003517-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003517-35.